Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:42 PM
Ignite Modification Date:
2025-12-24 @ 11:42 PM
NCT ID:
NCT04976751
Eligibility Criteria:
Inclusion Criteria:
* Patient meets the diagnostic criteria of National Institutes of Health (NIH)Ⅲ type prostatitis;
* NIH-CPSI score \> 10;
* The symptoms lasted for more than 3 months and failed to respond to drug treatment for more than 1 month;
* Age ≥18 years old and ≤60 years old agrees and signs the informed consent;
* Those who did not receive other similar treatment regimens during treatment.
Exclusion Criteria:
* All kinds of bacterial infection caused by acute or chronic orchitis or epididymitis, acute or chronic prostatitis, lower urinary tract infection;
* Benign prostatic hyperplasia, prostate cancer, neurogenic bladder, urethral malformation or stricture and severe neurosis;
* For patients with local pain as the main manifestation, attention should be paid to the exclusion of other lesions in the lower abdomen, perineum, lsosacral sites, such as ureteral calculi, bladder calculi, inguinal hernia, pubis, varicocele, epididymitis, rectocolic diseases, lsodorsal myofascitis, etc.;
* Complicated with heart, brain, liver and hematopoietic system and other serious primary diseases, local skin infection or skin lesions in the treatment site;
* People who have metal implants in their bodies cannot cooperate, such as patients with mental illness.
* People who are allergic to the treatment of electrical stimulation or allergic to a variety of drugs.
Healthy Volunteers:
False
Sex:
MALE
Minimum Age:
18 Years
Maximum Age:
60 Years
Study:
NCT04976751
Study Brief:
Protocol Section:
NCT04976751